LabCompass

Colleen M. Cebulla

Medicine · The Ohio State University

Established · publishing since 1999

Publications

228

Citations

42,792

Est. group size

~2

Recurring co-author estimate

Active years

28

Publishing since 1999

Research summary
AI-generated

Colleen M. Cebulla's research centers on eye diseases, especially uveal (eye) melanoma, proliferative vitreoretinopathy (a scarring disease affecting retinal detachment repair), and retinal degeneration. Her work spans laboratory studies of disease mechanisms and genetic risk, as well as clinical and translational research on cancer therapies and outcomes for eye conditions such as age-related macular degeneration and BAP1 tumor predisposition syndrome. This work draws on genomics, cell biology, and clinical case studies to better understand and treat ocular cancers and retinal disorders.

Uveal (eye) melanoma biology and geneticsRetinal degeneration and disease modelsProliferative vitreoretinopathy (scarring after retinal detachment)Ocular oncology treatments and clinical outcomesAge-related macular degeneration

Publication output was highest around 2018 and has generally declined since, with a notable dip between 2022 and 2024 followed by a modest uptick in 2025-2026.

Generated by claude-sonnet-5 from public bibliographic data · Jul 20, 2026

Publication cadence
Publications per year over the last 10 years — averaging 4.2/year recently
2017: 14 publications172018: 40 publications40182019: 18 publications192020: 11 publications202021: 12 publications212022: 6 publications222023: 1 publication232024: 1 publication242025: 7 publications252026: 6 publications26
Recent publications
Publishes in
  • Investigative Ophthalmology & Visual Science×22
  • Cell Reports×12
  • Cell×9
  • Cancer Cell×7
  • Ocular Oncology and Pathology×4
Similar researchers
By research-topic overlap

This profile was generated automatically from public scholarly data (OpenAlex). Group size and activity levels are estimates derived from co-authorship patterns.

Last updated Jul 19, 2026.

Claim or correct this profile